Testosterone Therapy and replacement products have become a media sensation. Endo Pharmaceuticals, Actavis, and Pfizer have all faced Testosterone Therapy lawsuits. However, they have all been unsuccessful in finding the responsible parties. In this article, we’ll discuss the latest developments in the lawsuits against these companies. The pharmaceutical companies have taken a beating in the recent media blitz, with commercials targeting men and women with breast cancer.
If you’re wondering if Endo Pharmaceuticals vs Testosterone Therapy is right for you, here are some things to consider. While this type of lawsuit will likely cost you more than $200 million, the company claims that it has accurately estimated its liability costs. The FDA advisory committee’s findings based on current data did not support the drug’s approval. Further, the advisory committee’s report could have been different if it had been presented with information about the potential cardiovascular risks of testosterone.
Endo Pharmaceuticals has already added $200 million to its legal reserves in anticipation of litigation and lawsuits relating to the testosterone hormone. The company reported last May that it is facing over 1,300 testosterone liability lawsuits. Of those, 900 are in multidistrict litigation involving Endo in the Philadelphia Court of Common Pleas, while the rest are filed in state courts. Plaintiffs allege that Endo overmarketed the testosterone drugs and failed to warn patients about the risks.
Although the FDA is not asking physicians to change their prescription habits, it has been reviewing the safety of testosterone treatment and has recently approved Aveed for use in treating hypogonadism. The company has been criticized for promoting the drug for off-label uses, including flagging male sex drives and normal aging conditions. Some argue that the drug has little to no benefit for these off-label uses and raises the risk of deadly side effects.
A lawsuit filed against Actavis Inc., a manufacturer of testosterone replacement therapy, has been successfully dismissed. The plaintiff, Brad Martin, claimed that the testosterone replacement therapy caused his heart attack. Actavis denied that the product was a cause of his heart attack, and the jury awarded Martin a defense verdict. The lawsuit alleges that Actavis failed to adequately warn consumers about the risks of Androderm.
In its MIL, Actavis seeks to exclude evidence about its financial condition and off-label marketing. Specifically, the company argues that certain kinds of evidence are irrelevant, and the Court should not allow them. Furthermore, Actavis claims that the Court should exclude evidence about off-label marketing, which is irrelevant to the plaintiff’s claims. But the company is appealing this decision, claiming that the plaintiff should not be forced to settle the case because of the absence of a viable defense.
Regardless of the outcome of the Actavis Testosterone Therapy lawsuit, the company has ample time to prepare for trial. Actavis has argued that the opinions of Dr. Sharlin were based on new information that did not exist at the time of her deposition. Martin has also argued that Actavis’s failure to disclose relevant information could confuse the jury. In the meantime, the Court deferred ruling on Martin’s eighth motion in limine.
In a report released by the U.S. Judicial Panel on Multidistrict Litigation in April 2019, the testosterone lawsuit is the ninth largest pending case. Many of the defendants, including Pfizer, AbbVie, Eli Lilly, Endo International, Auxilium Pharmaceuticals, and Teva, have settled thousands of cases, with one reaching a confidential global settlement with the FDA.
Another lawsuit filed against Pfizer has to do with testosterone. In 2014, the FDA warned bodybuilders of a potential risk of heart attack, stroke, and pulmonary embolism when using testosterone. This warning led to changes in the labeling of testosterone products. In 2015, the FDA required additional warnings on the label. The drugmaker will likely face further lawsuits related to the increased risk of these complications. Despite these recent developments, Pfizer continues to market testosterone products to men and women.
Thousands of patients have sued Pfizer for serious injuries caused by the use of testosterone replacement products. The FDA has ordered the makers to update the labels to warn patients about the risks of testosterone therapy. The FDA has said the drug makers must weigh the risks and benefits of the treatment against the potential side effects. As a result, these risks may change, but not before the FDA’s announcement. This lawsuit is actively being monitored by Hovde Dassow & Deets, a leading personal injury law firm in Indianapolis.